117 Comments
User's avatar
EP's avatar

There's a strong fascistic intolerance for dissent in psychiatry. We need more brave public voices that are willing to be critical. I hope you reconsider your conclusions. There is currently not sufficient RCT evidence on the long term benefits and withdrawal of SSRIs, unfortunately. Yet long term observational suggest a lot of people could be suffering from these drugs. Even worse, other meta analyses make it clear that only 16-25% of people experience improvements from SSRIs; but half of those are attributable to the placebo. So only 8-12% of people receive benefit after 12-36 weeks. Yet the typical experience is that SSRIs are taken for 3-5 years. We do not have enough RCT evidence to understand the effects and withdrawals after 3-5 years. The short-term RCTs make it clear that the vast majority of people will not receive any benefit from the SSRI, and those people should be advised to stop the SSRI immediately since the long term effects are unknown. Yet SSRIs have an unjustified reputation of being highly efficacious. This is a clear example of real world prescribing behavior not reflecting the evidence. And there aren't enough brave voices to even acknowledge the potential for this suffering

Expand full comment
Richard Feinman's avatar

This is not a subject for group statistics. There is no average withdrawal from antidepressants. And withdrawal from one may be followed with another. And the variability of knowledge, empathy, understanding of the therapist is large. This is not a field that can be analyzed in standard ways, if at all.

Expand full comment
Heather's avatar

Something I think Mandrola missed... This study only looked at number of symptoms, not severity, so if your existing side effects become far more severe that wouldn't count, and if you only had one additional symptom - which was I think the conclusion of the study which they determined was a non event - I'm telling you I've discontinued plenty of meds over 1 side effect that was intolerably severe, so the whole premise of this study that functions on counting symptoms but ignoring severity and calling 1 additional symptom irrelevant is f***ed!!!

Expand full comment
Meera Dawson's avatar

What is the link to the research article?

Expand full comment
Kelly Miller's avatar

Regarding "The main finding" - I never wanted to take my own life more than when I weaned off of desvenlafaxine. A miserable 6 weeks that badly bruised my marriage, found me in trouble at work, and required me to make a promise to my daughter that I wouldn't follow through.

Expand full comment
D Oliver's avatar

I haven’t read this study, but after years of treating patients, I’ve no doubt that discontinuation syndrome is a major issue, most often depending on which antidepressant was used. It can be a serious problem for the patient. Often can be mitigated by slow taper or adding one with long half life for 2-3 weeks, then discontinuing both. If this study lumped all antidepressants together, the effect may be lost in the weeds.

Expand full comment
LLS's avatar

It would be interesting to study (perhaps it's already been done)....the difference in male/female hormones as an influence on depression. I also think it would be interesting to study the age at which depression actually begins....to see if depression is the result of early childhood experiences...from birth....familial as well as hormonal...in girls vs. boys. And...of course....the difference in all early experiences in those who do suffer from depression vs. those who do not.

Expand full comment
Ernest N. Curtis's avatar

Calling any of this "science" is a serious misnomer. There are many obvious problems with attempting to quantify and compare subjective symptoms in a group of patients placed on medications for largely subjective symptoms. Doing a meta-analysis on all this just compounds the problems.

Expand full comment
Phil's avatar

Were there any conflicts of interest from any of the authors of the studies used in the meta-analysis? Also the study sponsors would be of interest.

Expand full comment
Steve Cheung's avatar

The meta analysis showed what it showed. Following generally short duration of use of these various SSRI’s, there was relatively little withdrawal symptoms during very short term (1-2 week) follow up.

It does very little to address issues with long term users, because few of the included studies had such a cohort. And it doesn’t examine symptom prevalence farther removed from med discontinuation.

So this may be part of the puzzle but does not dispel the “withdrawal” phenomenon in anywhere close to its entirety.

Expand full comment
David AuBuchon's avatar

If this paper were legitimate, sice most trials were short term, then the fact relapse allegedly did not occur would indicate that long-term drug treatment should not be a thing. Either way, the field has some 'splaining to do.

Expand full comment
Odette Hélie's avatar

I have read that often the withdrawal symptoms are mistaken for the return of the original pathology and so the patient is rapidly returned on medication. If (a big if) it is true it is dramatic. I also know many people who have tried many times to taper off but since this must be done really really gradually (possible to cut the pills but it seems that they are very sensible to oxydation) it is quite difficult. I am not impressed by the study protocol.

Expand full comment
Disa sacks's avatar

Millions of prescriptions for SSRIs are given to ppl for non psychiatric reasons( migraines, insomnia, neuropathy, fibromyalgia and others)

Many of these ppl experience the same debilitating withdrawal problems

Thieve drugs were marketed under the false “ chemical imbalance “ assertion

They hid the PSSD problems

They were largely studied for short

There is mounting evidence that SSRIs are deleterious to a developing fetus

One could easily make the case that these drugs should be much more tightly regulated or even pulled off the market for deceptive practices

Expand full comment
Mark Horowitz's avatar

I am a fan of John's work in general. But he has been badly misled by this review. The main conclusions from this study were based on 8-12 week studies, nothing like the years or decades people use these drugs for. There is a clear association between duration of use and risk of withdrawal. This was an attempt to mislead and minimise a serious public health issue causing embarrassment to establishment academics who have been reassuring the public and doctors for decades that there is no issue. It is reminiscent of a similar tactic for opioids where Purdue highlighted 'low rates of addiction' based on poorly conducted studies.

https://theconversation.com/antidepressant-withdrawal-new-review-downplays-symptoms-but-misses-the-mark-for-long-term-use-260708

Expand full comment
Christine wildman's avatar

I agree with you. I work with people daily who have difficulty for many weeks even when tapering from SSRI’s and I am someone who took Paxil in the early days before the discontinuation symptoms were reported and had severe symptoms even after only a few years on it while trying to taper. They thought I had a virus of some sort until I went back to my original dose and it was all gone. The symptoms were completely debilitating- nausea , dizziness, agitation, and the brain zaps cannot be overstated.

Expand full comment
Percy Malinki's avatar

Well said! The people who've been on SSRIs for years should not be 'reassured' that agomelatine has no withdrawal syndrome...

Expand full comment
Dr Michael Sikorav's avatar

I'm a psychiatrist seeing 200+ patients a week, doing pharmacology only, and I can tell you that study doesnt bring anything new or reasuring to the field

Let me know if you're interested in a more extensive write up

Expand full comment
Freddie deBoer's avatar

That is not scientific evidence

Expand full comment
Dr Michael Sikorav's avatar

Of course it isnt

It's just a way of disclosing my own bias in favor of psychopharmacology - but even with that bias, I can see there are a few things that went wrong with this study

Expand full comment
Michael Schachter's avatar

“Good news Mr. Johnson! Those debilitating brain zaps you are experiencing are not clinically significant!”

Expand full comment
Freddie deBoer's avatar

SSRIs do not "zap" brains, and ECT is an essential treatment for severe depression

Expand full comment
Disa sacks's avatar

ECT is wholly unscientific

There is zero basic science to support it

The clinical literature is of very low quality.Very few RCTs , the last in the 1980s. Almost all “ studies” had no follow up beyond one month

The rest of the publications are case series - with only the psychiatrist report of “ success” . No patient follow up

ECT machines have never been through FDA approval - they were grandfathered in decades ago on the say so of the psychiatrist who owned the company that manufactures the machines!!!

ECT in practice today in America has no monitoring and no reporting

There is no follow up of the patients , regardless of where the ECT is done( teaching hospital vs small for profit free standing psych facilities ( UHS-United Hospital Systems owns hundreds of these throughout the country)

When ppl who are severely harmed by ECT try to report the problems( severe permanent retrograde amnesia and cognitive dysfunction and more) they are told” ECT doesn’t do that it’s your underlying diagnosis “ denigrated and abandoned .

ECT is barbaric it should be banned

Read the Castleman report 2018

https://www.madinamerica.com/wp-content/uploads/2021/01/3Castleman_2018_Expert-Report.pdf

Expand full comment
Isobel Gowdie's avatar

Brain zaps have nothing to do with ECT Freddie. What on EARTH.

Expand full comment
Murphmitch's avatar

Exactly! Electrical shocks was the exact words my child described to me trying to go of his SSRI's.

Expand full comment